NCCN Guidelines® Insights - Melanoma, Version 2.2013
The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the novel agents ipilimumab and vemurafenib for treatment of advanced melanoma. As well, the NCCN panel included imatinib as a treatment for KIT-mutated tumors and pegylated interferon alfa-2b as an option for adjuvant therapy. Also important are revisions to the initial stratification of early-stage lesions based on the risk of sentinel lymph node metastases and revised recommendations on the use of sentinel lymph node biopsy for low-risk groups. Finally, the NCCN panel has reached clinical consensus on clarifying the role of imaging in the work-up of melanoma patients.
This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for Melanoma
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Melanoma
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician